The symposium exploring advances in cancer
prevention and care is set to take place on March 4, International HPV Awareness Day, in
Baroda, India
SALT
LAKE CITY, March 3, 2025 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests, today
announced that the Company and CoSara Diagnostics Pvt. Ltd.
("CoSara"), the joint venture between Ambalal Sarabhai Enterprises
Limited (ASE Group) and Co-Dx, will be hosting a symposium to honor
International HPV (human papillomavirus) Awareness Day 2025.
Titled "HPV and Cancer: Exploring Advances in Prevention and
Care," the one-day symposium will take place on Tuesday, March 4, 2025 in Baroda, India. The program will include speakers from
Co-Dx and CoSara, as well as experts in cancer, cancer diagnostics
and oncology from across India.
International HPV Awareness Day is observed annually on
March 4, with the goal of educating
the public about HPV, reducing the stigma of the virus, and
empowering individuals and society to take action to reduce its
harm.
The National Cancer Institute estimates that high-risk HPV
subtypes cause roughly 5% of all cancers worldwide. This includes
cervical cancer, the fourth most common cancer in women, which led
to an estimated 350,000 cervical cancer deaths in 2022 according to
the WHO. About 94% of these deaths are in low- and middle-income
countries ("LMICs"), which the WHO believes can be dramatically
reduced by access to diagnostics, vaccinations, and cancer
screenings.
The symposium comes as Co-Dx completes the assay development
stage for its HPV multiplex test on the Co-Dx PCR point-of-care
platform* in preparation for pre-clinical and pre-analytical
studies. The test is designed to utilize Co-Dx Co-Primers®
technology and the unique architecture of the Co-Dx PCR Pro
instrument to identify 8 high-risk HPV subtypes from cervical swab
samples, with the goal of providing an affordable, accessible HPV
screening tool for patients around the world, especially in
LMICs.
"Early diagnosis of illnesses can not only lead to earlier, more
effective treatments and trigger patients to begin regular cervical
cancer screenings, it can also form a vital component in limiting
the spread of viruses like HPV," commented Dwight Egan CEO of
Co-Dx. "We are pleased with the progress we have made on the HPV
multiplex test and the preliminary performance data seen so far,
and we are honored to participate with our joint venture partner in
this symposium to raise awareness of this important health
concern."
CoSara CEO Mohal Sarabhai added
"In alignment with the missions of the joint venture partners,
CoSara is committed to a world with increased access to
high-quality infectious disease diagnostics. We believe that
providing a forum for leading experts in fields like HPV and cancer
to share knowledge with other researchers, physicians, oncologists
and industry leaders advances the cause of disease prevention and
global health."
CoSara's Saragene® Human Papillomavirus-High Risk real-time PCR
test has been cleared by the Indian CDSCO for use as an IVD in
clinical laboratories in India to
detect and differentiate HPV high-risk genotypes 16 and 18.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™,
mobile app, and all associated tests) is subject to review by the
FDA and/or other regulatory bodies and is not yet available for
sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
identify genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Forward-looking statements include
statements made with respect to our Co-Dx PCR platform and the
development of an HPV multiplex test. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Forward-looking statements are subject to inherent
uncertainties, risks and changes in circumstances. Actual results
may differ materially from those contemplated or anticipated by
such forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the
SEC. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
Please note that we disclaim any responsibility for the
content of external links provided in this press release. These
links are provided solely for the reader's convenience and do not
constitute an endorsement by the Company.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-and-cosara-to-host-hpv-and-cancer-symposium-on-international-hpv-day-2025-302389836.html
SOURCE Co-Diagnostics
